# Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

> **NCT01478581** · PHASE2 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 92 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** PCI-32765
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01478581
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2020-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01478581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01478581, "Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01478581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*